MT1 BET inhibitor
MT1 BET inhibitor Basic information
- Product Name:
- MT1 BET inhibitor
- Synonyms:
-
- 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N,N'-3,6,9,12,15,18,21-heptaoxatricosane-1,23-diylbis[4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S,6'S)-
- MT1 BET inhibitor
- CAS:
- 2060573-82-0
- MF:
- C54H66Cl2N10O9S2
- MW:
- 1134.2
- Mol File:
- 2060573-82-0.mol
More
Less
MT1 BET inhibitor Chemical Properties
- Density
- 1.39±0.1 g/cm3(Predicted)
- form
- Solid
- pka
- 14.57±0.46(Predicted)
- color
- Off-white to light yellow
- InChIKey
- JNSLBXJNVHYNNW-CXNSMIOJSA-N
- SMILES
- C(NC(=O)C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C2C(C)=C(C)SC=2N2C(C)=NN=C21)COCCOCCOCCOCCOCCOCCOCCNC(=O)C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C2C(C)=C(C)SC=2N2C(C)=NN=C21
More
Less
MT1 BET inhibitor Usage And Synthesis
Uses
MT1 is a bivalent chemical probe of BET bromodomains, with an IC50 of 0.789 nM for BRD4(1)[1].
in vivo
MT1 (44.2 and 22.1 μmol/kg, ip daily, for 14 days) significantly delayed leukemia progression in mice (Mus musculus) compared to JQ1[1].
MT1 exhibits terminal t1/2 of 2.70 h in mice[1].
| Animal Model: | Leukemia xenograft models[1]. |
| Dosage: | 44.2 and 22.1 μmol/kg. |
| Administration: | Intraperitoneally for 14 subsequent days. |
| Result: | Significantly reduced leukemic burden over the course of the study compared to either vehicle or JQ1. |
References
[1] Minoru Tanaka, et al. Design and characterization of bivalent BET inhibitors. Nat Chem Biol. 2016 Dec;12(12):1089-1096. DOI:10.1038/nchembio.2209
MT1 BET inhibitorSupplier
Beijing Biocreative Technology Co., Ltd.
- Tel
- 15522676233
- 3007606172@qq.com
RD International Technology Co., Limited
- Tel
- 18024082417
- market@ubiochem.com
Biosynth Biological Technology (Suzhou) Co Ltd
- Tel
- 51288865780
- sales@biosynth.com
Shanghai Yimeixin Technology Co., LTD
- Tel
Kebeilai Pharmaceutical Biotech Co., Ltd.
- Tel
- +86-18240866958
- wangjasmine7289@gmail.com